Skip to main content
Clinical Trials/NCT00667979
NCT00667979
Completed
Phase 4

A Pilot, Randomized, Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy and Safety of Vardenafil Versus Placebo Administered 12, 18 and 24 Hours Prior to Initiation of Sexual Intercourse in Subjects With ED

Bayer0 sites264 target enrollmentSeptember 2004

Overview

Phase
Phase 4
Intervention
Levitra (Vardenafil, BAY38-9456)
Conditions
Erectile Dysfunction
Sponsor
Bayer
Enrollment
264
Primary Endpoint
Sexual encounter profile Question 3
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. However, there remains no prospectively obtained data on the maximal time of effectiveness of vardenafil. The goal of the current study was to determine if vardenafil will significantly increase the percentage of successful intercourse attempts from 12 to 24 hours following dosing. A total of three time points 12, 18, and 24 hours were assessed in this pilot study to better quantify the effect of vardenafil.

Registry
clinicaltrials.gov
Start Date
September 2004
End Date
December 2004
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Sponsor
Bayer

Eligibility Criteria

Inclusion Criteria

  • Men \>/= 18 years of age
  • ED \>/= 6 months
  • Stable sexual relationship for \> 6 months

Exclusion Criteria

  • Primary hypoactive sexual desire
  • History of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 month
  • Nitrate therapy
  • Other exclusion criteria apply according to the Summary of Product Characteristics

Arms & Interventions

Arm 1

Intervention: Levitra (Vardenafil, BAY38-9456)

Arm 2

Intervention: Placebo

Outcomes

Primary Outcomes

Sexual encounter profile Question 3

Time Frame: 6 weeks

Secondary Outcomes

  • Safety and Tolerability(6 weeks)

Similar Trials